Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier
about
Small and Innovative Molecules as New Strategy to Revert MDRCentral neurotoxicity in cancer chemotherapy: pharmacogenetic insights.P-glycoprotein induction in Caco-2 cells by newly synthetized thioxanthones prevents paraquat cytotoxicity.Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.Factors that limit positron emission tomography imaging of p-glycoprotein density at the blood-brain barrier.A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects.Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113.Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomographyRadiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance proteinSynthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoatePET and SPECT radiotracers to assess function and expression of ABC transporters in vivoPilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain BarrierThe Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy.PET radiotracers for imaging P-glycoprotein: the challenge for early diagnosis in AD.Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier.Radiopharmaceuticals for assessing ABC transporters at the blood-brain barrier.Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions.A benzopyrane derivative as a P-glycoprotein stimulator: a potential agent to decrease β-amyloid accumulation in Alzheimer's disease.Assessment of P-glycoprotein activity in the Blood-Brain Barrier (BBB) using Near Infrared Fluorescence (NIRF) imaging techniques.Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.Synthesis and In Vivo Imaging of N-(3-[11C]Methoxybenzyl)-2-(3-Methoxyphenyl)ethylaniline as a Potential Targeting Agent for P-glycoprotein.Small-animal PET evaluation of [11C]MC113 as a PET tracer for P-glycoprotein.Induction and activation of P-glycoprotein by dihydroxylated xanthones protect against the cytotoxicity of the P-glycoprotein substrate paraquatATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?
P2860
Q27012455-5A52EB3B-F709-4F82-B7BA-DB3096D1776CQ33857581-C1DFA824-7A1D-4A37-AA3A-BFEA636FECF5Q35262608-EB628239-8DE2-4A08-9F4E-94FEAA686679Q36638627-8F08A601-6B98-4936-B928-A63576D17FC3Q36717122-3050A7E9-A8D6-4DBE-87EA-84E054ECC8DBQ36910890-44A02AB4-7BAA-491E-8C4D-EA2A004E5926Q36935382-2B05D113-8735-42DB-9385-E9F56222F0BDQ36947636-C611984B-523A-48CB-847C-79B638C41D10Q36947641-A42AEA06-F221-4D51-A523-5EAF20D74C3EQ36949082-241E5AD0-1889-4E80-8241-7E6B2C487D56Q36949086-877190E4-9BE4-4E65-BDDB-4546B5D63501Q36949407-89E81400-A456-4E27-9ED1-FCD6A2F5F9ABQ36949859-64303E13-69FE-45E5-9045-699FC8A0435BQ36949864-9495D0CA-06BD-43A4-A692-E9323B3257D3Q36953090-8E105275-0E45-4D38-B0B3-38DDE3B3F0B5Q37164563-470A43A2-803A-4EE0-9FEC-4C44DDEB415BQ37576360-6FF7290F-187E-4AA6-8535-472BF347C08CQ38156720-005A7FAF-A499-4CB5-9215-00E622231EF3Q38166961-B7324947-9DF5-4EDC-A385-8F4FADD8273AQ38351240-CF6799A4-8E8A-4010-856B-620B706D29D3Q38844653-1F27E9FB-D489-4864-9CF0-6791BEA376C5Q39418372-87DCBC4F-932E-45BC-938B-ED9BCB1F4391Q39539362-CC18B9C0-E7C1-4E8D-BC2E-355A7178F145Q41775684-F371A7CE-B92F-4F2A-A98B-FB6AAAF4640FQ52964010-D2530366-8852-403C-8375-5C4FBF6D36E0Q55462443-D7293E1C-1414-4CE8-ADBB-63F17E3235CCQ58296783-F608F528-E208-4A0D-8FBA-2752CD5A3E2AQ58798114-198A3038-2B90-4038-A223-C875B3526570
P2860
Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Synthesis and small-animal pos ...... ein at the blood-brain barrier
@en
type
label
Synthesis and small-animal pos ...... ein at the blood-brain barrier
@en
prefLabel
Synthesis and small-animal pos ...... ein at the blood-brain barrier
@en
P2093
P2860
P50
P356
P1476
Synthesis and small-animal pos ...... ein at the blood-brain barrier
@en
P2093
Bernd Dörner
Gloria Stundner
Jens P Bankstahl
Johann Stanek
Markus Müller
Thomas Erker
Thomas Wanek
Wolfgang Löscher
P2860
P304
P356
10.1021/JM900940F
P407
P577
2009-10-01T00:00:00Z